Ozuriftamab BA302 represents a groundbreaking advancement in cancer therapy. This unique antibody-drug conjugate selectively targets B-cell maturation antigen, a key protein expressed on multiple myeloma cells and some lymphatic types. Its mechanism of action involves … Read More

Tiragolumab, a innovative protein, is currently undergoing extensive clinical evaluation for its capacity to modulate the PD-1/PD-L1 relationship. Its development aims on enhancing the efficacy of current PD-1 inhibitors , particularly in unresponsive cancer subjects. Early results suggest a enco… Read More